Multiple Analytical Approaches Demonstrate a Complex Relationship of Genetic and Nongenetic Factors with Cisplatin- and Carboplatin-Induced Nephrotoxicity in Lung Cancer Patients
Table 1
Comparisons between the cases and controls.
Cases
Controls
ORa
95% CI
value
Number (%)
Number (%)
Total
28
88
Gender
0.96
Male
17 (60.7)
53 (60.2)
Female
11 (39.3)
35 (39.8)
Age (years)
Mean ± SD
63.43 ± 9.47
66.66 ± 11.64
0.19
≥60
17 (60.7)
64 (72.7)
0.23
<60
11 (39.3)
24 (27.3)
Weight (kg)
Mean ± SD
59.6 ± 10.9
58.0 ± 9.78
0.48
Alcohol consumption
3 (10.7)
11 (12.5)
0.80
Smoking
13 (46.4)
36 (40.9)
0.61
Baseline Scr (mg/dL)
Mean ± SD
0.83 ± 0.36
0.91 ± 0.32
0.22
Treatment regimen
G + C/Cb
20 (71.4)
63 (71.6)
0.99
P/D + C/Cb
8 (28.6)
20 (22.7)
0.52
E + C/Cb
3 (10.7)
8 (9.1)
0.73
V + C/Cb
10 (35.7)
16 (18.2)
0.05
CCRT
2 (7.1)
5 (5.7)
0.68
Other
3 (10.7)
8 (9.1)
0.73
Number of cycles
Mean ± SD
4.96 ± 1.95
4.16 ± 1.65
0.034*
ERCC1 C118T
CC
14 (27.5)
37 (72.5)
Ref
CT
10 (18.2)
45 (81.8)
0.29
0.09~1.00
0.05
TT
4 (40.0)
6 (60.0)
0.77
0.15~3.93
0.76
CT + TT
14 (21.5)
51 (78.5)
0.37
0.12~1.14
0.08
TP53 Arg72Pro
Arg/Arg
12 (38.7)
19 (61.3)
Ref
Arg/Pro
12 (19.4)
50 (80.6)
0.38
0.12~1.26
0.11
Pro/Pro
4 (17.4)
19 (82.6)
0.34
0.07~7.44
0.18
Arg/Pro + Pro/Pro
16 (18.8)
69 (81.2)
0.37
0.12~1.17
0.09
SD: standard deviation; Scr: serum creatinine; C: cisplatin; Cb: carboplatin; G: gemcitabine; P: paclitaxel; D: docetaxel; E: etoposide; V: vinorelbine; CCRT: combined chemoradiotherapy.
aThe odds ratio (OR) and 95% confidence interval (CI) were adjusted for age, gender, body weight, alcohol consumption, smoking, baseline Scr, treatment regimen, number of chemotherapy cycles, histology, and cancer type.
*
.
